Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
  • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
  • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
  • G01N33/5047—Cells of the immune system
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Definitions

• Successful therapy with a pharmaceutical agent requires that the agent satisfy numerous requirements imposed by the physiology of the host and of the disease or condition.
• the requirements include: (i) adequate ability to interact with the target receptor(s); (ii) appropriate physical properties for presence at the location of the receptors in concentrations that permit the interactions noted above; (iii) appropriate physical properties to allow the agent to enter the body and distribute to the location of the receptors by any means; (iv) sufficient stability in fluids of the body; (v) the absence of toxic effects in compartments where the therapeutic agent is most concentrated, or in any other compartment where the therapeutic agent is located; and (vi) the absence of sequestration into non-physiological compartments and so on.
• Certain delivery strategies involve a physical preparation such as liposomes (Debs et al. 1990; Jaafari, Foldvari, 2002) or anti-body conjugates (Everts et al., 2002) which further direct the molecules within the host body.
• Others rely on the addition of cationic lipids to formulations, the use of transport proteins as a route of uptake (WO 01/20331).
• transport proteins as a route of uptake (WO 01/20331).
• the use of transport processes deliberately in therapeutic agent design is perhaps best illustrated by the nucleoside therapeutic agents, which to varying degrees, are taken up as metabolites and whose transport to mitochondria is a major cause of toxicity (WO 98/29437) For example, see European Patent No. 0009944B1, European Patent No. 0044090A3, and Japanese Patent No. 05163293.
• Such methods may enhance performance in therapy or reduce toxicity but they increase cost and require direct introduction into the blood stream which is impractical in chronic use.
• More preferable would be small molecules that possess the appropriate structures and properties to mediate efficient uptake and stability. Such small molecules would ideally be able to carry a range of therapeutic agents of varying properties such that they could be commercialized in more than one indication. However, there is a requirement that they be inactive and stable enough to ensure that the cargo molecule is carried in the periphery (Harada et al. 2000).
• the present invention represents a significant advance in that it provides for a means of improving the bioavailability and efficacy of a variety of molecules in vivo using a series of rational and facile assays to select desirable compounds based on known pharmacophores or pharmaceutical lead structures that have not been optimized for in vivo action.
• the invention relates to a compound useful for enhancing efficacy of a therapeutic agent, a method for identifying such a compound, and a method of treating diseases including inflammation, graft rejection, infection, cancer, allergies, metabolic cardiovascular, pulmonary,dermatological, rheumatological and hepatic diseases.
• the invention further comprises compositions and formulations selected using the method and applications for same.
• the invention provides for a method for identifying compounds that act as carriers or "transportophores" (i.e., a transport mediating molecule) that when combined, either directly or via a linker, to a wide variety of therapeutic agents, improves one or more of the following characteristics of the agent: ease of formulation, gastric stability, bioavailability, stability, disposition, elimination, half life, efficacy, safety, duration of action and selectivity.
• this invention features a compound of the following formula (or referred to as T-L-C hereinafter):
• T is a transportophore
• L is a bond or a linker having a molecular weight up to 240 dalton
• C is a non-antibiotic therapeutic agent
• m is 1, 2, 3, 4, 5, 6, 7, or 8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2.
• m is greater than 1
• the L moieties or the C moieties independently, can be the same or different. The same rule applies to other similar situations.
• the transportophore can be a metabolite, a natural product, a metabolite mimic, a metabolite derivative (e.g., a sugar, amino, or peptide derivative), a fatty acid, a bile acid, a vitamin, a nucleobase, an alcohol, or an organic acid or base, a portion of which resembles and is recognized as a substrate for transport protein(s).
• It can be an amphiphilic molecule having a pKa value of 6.5 to 9.5, or a cyclic or heterocyclic molecule (e.g., lactone, lactam, ether, cyclic acetal or hemi-acetal).
• the cyclic or heterocyclic molecule can have an attached sugar.
• the cyclic or heterocyclic molecule can be a macrolactone or macroether, including a macrolactone or macroether having an attached sugar.
• the cyclic or heterocyclic molecule can also be a macrolide or ketolide having an amino sugar, including a macrolide having mono-, di-, or tri-basic groups (e.g., an amine).
• the macrolide has no intrinsic antibacterial activity (inactive at 50 uM or higher concentrations when tested against Bacillus invitro see protocol) and apKa value of less than 9.0 (e.g., 8.5, 8.0, 7.5, 7.0, or any number in between).
• the compound has the following formula (in which a bond, drawn without any attached groups, means a methyl group. The same rule applies to other similar situtations):
• (Ci -C 4 )alkyliden-NR 18 R 19 wherein alkyl, alkenyl, alkynyl, aryl, and heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C ⁇ -C 4 )alkyl, ( - C 4 )alkenyl, (C ⁇ -C 4 )alkynyl, (C 3 -C )cycloalkyl, (C ⁇ -C 6 )heterocycloalkyl, (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C ⁇ -C 4 )alkoxy, hydroxy, nitro, cyano, azido, mercapto, -NR 18 R 19 ,
• R 9 H (C C ⁇ o)alkyl
• R 10 , R 11 independently H
• R 12 H (C ⁇ -C ⁇ o)alkyl
• R 17 O-R 20 -aryl optionally substituted by-X'-Y- therapeutic agent, X'- therapeutic agent wherein X' is S
• R 18 , R 19 independently H (C ⁇ -C ⁇ o)alkyl
• the compound has the following formula:
• alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl can optionally be substituted by one to three halogen, cyano, hydroxy, (C ⁇ -C )alkyloxy, nitro, (d-C ⁇ alkyl, (C ⁇ -C 6 )alkenyl, (C ⁇ -C 6 )alkynyl, (C 3 -
• R ⁇ a , R independently H R 1 OH OR 11
• R 10 , R 11 independently H
• R 17 O-R 20 -aryl optionally substituted by -X'-Y- therapeutic agent, X'- therapeutic agent wherein X' is
• R 18 , R 19 independently H
• R 20 independently,
• the compound has the following formula:
• R 1 is connected to the oxygen bearing R 4 or R 5 forming a lactone or is connected to a suitable substituent in R 2 forming a lactone or lactam.
• (C 6 -C 10 )aryl (d-d ⁇ eteroaryl wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (d-C 4 )alkyl, (C ⁇ -C 4 )alkenyl, (d-C 4 )alkynyl, (C 3 -C 7 )cycloalkyl, (Ci-
• (d-C 9 )heteroaryl wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C ⁇ -C 4 )alkyl, (d-C 4 )alkenyl, (d-C 4 )alkynyl, (C 3 -C 7 )cycloalkyl, (d- C 6 )heterocycloalkyl, (C 6 -C 10 )aryl, (C ⁇ -C 9 )heteroaryl, (d-C 4 )alkoxy, R 20 R 21 N-
• R 6 , R 8 independently H
• (C 3 -C 10 )cycloalkyl (C i -C 9 )heterocyclo alkyl (C 6 -C 10 )aryl (d -C 9 )heteroaryl wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (C ⁇ -C 4 )alkyl, (C ⁇ -C 4 )alkenyl, (C ⁇ -C 4 )alkynyl, (C 3 -C 7 )cycloalkyl, (d- C 6 )heterocycloalkyl, (C 6 -C 10 )aryl, (C ⁇ -C 9 )heteroaryl, (d-C 4 )alkoxy, hydroxy, nitro, cyano, azido, mercapto, R 20 R 21 N-, R 20 C( O)-
• alkyl, alkenyl, alkynyl groups are optionally substituted by one to five substituents selected independently from halogen, (C ⁇ -C 4 )alkyl, (C ⁇ -C 4 )alkenyl, (Ci- C )alkynyl, (C 3 -C 7 )cycloalkyl, (C ⁇ -C 6 )heterocycloalkyl, (C 6 -C 10 )aryl, (d-C 6 )alkynyl, wherein alkyl, alkenyl, alkynyl groups are optionally substituted by one to five substituents selected independently from halogen, (C ⁇ -C 4 )alkyl, (C ⁇ -C 4 )alkenyl, (Ci- C )alkynyl, (C 3 -C 7 )cycloalkyl, (C ⁇ -C 6 )heterocycloalkyl, (C 6 -C 10 )aryl, (d-
• R 12 , R 13 independently H (d-C 6 )alkyl (C ⁇ -C 6 )alkenyl (d-C 6 )alkynyl (C 3 -C 10 )cycloalkyl
• R 14 independently therapeutic agent H
• (C ⁇ -C 9 )heteroaryl wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl groups are optionally substituted by one to five substituents selected independently from halogen, (d-C )alkyl, (C ⁇ -C 4 )alkenyl, (d-C )alkynyl, (C 3 -C 7 )cycloalkyl, (d-
• R 17 , R 18 independently H
• R and R then can represent a fragment from the type of -[C(AB)] m - ⁇ n -[C(DE)] 0 - ⁇ p -[C(GJ)] q wherein m, n, o, p and q independently are 0, 1, 2, 3, 4, 5, or 6, ⁇ and ⁇ independently are -O-, -S-, -NK- and A, B, D, E, G, J, and K independently are hydrogen, (C ⁇ -C 4 ) alkyl, (C ⁇ -C 4 )alkenyl, (d-C 4 )alkynyl, (C 3 -C 7 )cycloalkyl, (d-C 6 )heterocycloalkyl, (C 6 -C 10 )aryl, (d- C 9 )heteroaryl, (C ⁇ -C 4 )alkoxy, hydroxy, nitro, cyano, azido, mer
• R 20 , R 21 independently H
• R 22 independently
• the compound has the following formula:
• R 1 independently, H (C ⁇ -C 10 )alkyl optionally substituted by fluoro, cyano, R 4 , R 4 O 2 C,
• R 2 , R 3 independently NH 2 NHR
• R 9 wherein * is no or a positive charge, one or two of R , R can be a directly coupled therapeutic agent
• R 4 independently
• R 5 , R 6 independently H
• R independently, therapeutic agent
• R 9 independently, (d-C 6 ) alkyl (C 2 -C 12 )alkenyl (C 2 -C 12 )alkynyl (C 3 -Ci 0 )cycloalkyl(d -C 6 )alkyl
• Preferred molecules can be compounds that are recognized by a transport enzyme in the membrane of the cell of the tissue that is to target. This can be a molecule that fulfills the structural requirements in order to be recognized by an oligo-peptide transporter.
• R may represent a chemical residue that will modify the recognition by the transporting enzyme or at least not inhibit it.
• R may be comprised of the therapeutic agent that is to be delivered or the pharmaceutical entity is for example an amino acid itself as in example A.
• Necessary for transport through an oligopeptide transporter seems to be a basic group spaced 4 or 5 bonds from an hydrogen bond accepting group like preferably carboxylate (example A-C) or less preferred amide (example D).
• Ri and R 2 are hydrogen or lower alkyl, branched or linear from Ci to C 5 , or benzyl or p-hydroxy benzyl, or hydroxy or mercapto methyl, or any group responsible for the desired pharmacological effect.
• Example D R2 can be hydrogen or lower alkyl, branched or linear from Cl to C5, or benzyl or p-hydroxy benzyl, or hydroxy or mercapto methyl, while Rl consists of the pharmacologically relevant therapeutic agent.
• the therapeutic agent would contain a carboxylic acid that by linking to the amino function of an amino acid hydrazide would obtain the general structure of example D.
• Therapeutic agents and Transportophores can be directly connected or via a linking element.
• This element typically is a bifunctional molecule of low molecular mass, which can react subsequently with the therapeutic agent and the transportophore.
• the therapeutic agent can be released from this linker under physiological conditions. This may be achieved oxidatively (i.e. by action of a cytoclirome C), reductively (i.e. by action of NADH), hydrolytically (i.e. by action of a protease), or initiated by radicals (i.e. by the action of superoxide radicals).
• the mechanisms of therapeutic agent release are not limited to the above examples.
• F 1 , F 2 independently a functional group, suitable to react with a counterpart
• F and F are, but are not limited to
• R a is (C ⁇ -C )alkyl or aryl, optionally substituted by 1-5 halogen atoms;
• F and F can be connected to form a cyclic anhydride or di- or bisulfide.
• M is a spacing element which is, but is not limited to (d-C 8 )alkyl, (C ⁇ -C 8 )alkenyl, (C ⁇ -C 8 )alkynyl,
• Alkyl-, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl spacing elements are optionally substituted by (C ⁇ -C 6 )alkyl, 1-4 halogens, (d-C 4 )alkoxy, (Ci- C 4 )alkoxycarbonyl, hydroxy, amino, (d-C 4 )alkylamino, (CrC 4 )dialkylamino, (C - C 10 )cycloalkyl, (C 1 -C 6 )alkylcarbonyloxy, (d-C ⁇ alkylcarbonylamido, (d- C 4 )alkylamidocarbonyl, (C 1 -C 4 )dialkylamidocarbonyl, nitro,
• the donor linking function in vertical refers to a functional group on T; the recipient linking function in horizonal refers to a functional group on L; and the chemical groups in the boxes are the linkers (L).
• the non-antibiotic therapeutic agent can be an anti-inflammatory agent, an anti-infectious agent (including anti-virals), an anti-cancer agent, an allergy- suppressive agent, an immune-suppressant agent, an agent for treating a hematopoietic disorder, a lipid lowering agent, an agent for treating a lysosomal storage disorder, a sterol synthesis modifying agent, agents active on protozoa, or an agent for treating a metabolic disease.
• an “immune selectivity ratio” is the ratio of the concentration of a compound in immune cells (e.g., neutrophils, monocytes, and lymphocytes) to the concentration of the compound in erythrocytic cells after the compound has been incubated in a mixture of blood cells including erythrocytes.
• a protocol of determining the immune selectivity ratio is described in Example 1.
• a “therapeutic agent,” as used herein, is a molecule with pharmacological activity (e.g., a therapeutic agent, medicine, medicament, or active agent), a disease modification agent, or any other molecule that can be covalently attached to a transportophore via a bond or a linker which may have a desirable mode of action in immune or target cells.
• a therapeutic agent may be released from a compound described above in response to the enzyme activity or the physicochemical environment of the targeted cells.
• the therapeutic agent is selectively accumulated in a cell due to specific characteristics of the cell membranes, specific expression of membrane proteins, specific conditions within the cell, notably to expression of specific proteins such as granule proteins, binding sites in the cytoplasm, or other membrane bound or soluble proteins, and is thus trapped in the cell and therefore exhibits an enhanced or desired activity therein.
• amphiphilic molecule is a molecule having a hydrophilic (polar) and hydrophobic (non-polar) functional groups (e.g., atoms) or a combination of groups (or atoms).
• the pKa of this molecule is in the range of 6.5 to 9.5.
• cyclic refers to a hydrocarbon cyclic ring including fully saturated, partially saturated, and unsaturated mono-, bi-, and tri-cyclic rings having 4 to 34 ring atoms, preferably, 7 to 10, or 10 to 15 ring atoms.
• heterocyclic refers to a hydrocarbon cyclic ring including fully saturated, partially saturated, and unsaturated mono-, bi, and tri-cyclic rings having 4 to 34 ring atoms, preferably, 7 to 10, or 10 to 15 ring atoms having one or more heteroatoms, such as S, O, or N in each ring.
• sugar refers to a mono-, di-, or tri-saccharide including deoxy-, thio-, and amino-saccharides.
• sugar include, but are not limited to, furanose and pyranose.
• halogen and halo refer to radicals of fluorine, chlorine, bromine or iodine.
• macrolactone refers to a large lactone ring (i.e., cyclic ester) having at least 10 (e.g., 10 to 25) ring atoms.
• crocyclic ether refers to an ether having at least 10 (e.g., 10 to 25) ring atoms.
• the term "macrolide” refers to a chemical compound characterized by a large lactone ring (having at least 10, e.g., 10 to 25 ring atoms) containing one or more keto and hydroxyl groups, or to any of a large group of antibacterial antibiotics containing a large lactone ring linked glycosidically to one or more sugars; they are produced by certain species of Streptomvces and inhibit protein synthesis by binding to the 50S subunits of 70S ribosomes. Examples include erythromvcin, azithromycin, and clarithromycin.
• ketolide refers to a chemical compound characterized by a large lactone ring (having at least 10 ring atoms) containing one or more keto groups.
• alkyl refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms.
• Ci-do indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it.
• Alkenyl groups and alkynyl groups have one or more double or triple carbon-carbon bonds, respectively, in the chain.
• aryl refers to a hydrocarbon ring system (mono-cyclic or bi-cyclic) having the indicated number of carbon atoms and at least one aromatic ring.
• aryl moieties include, but are not limited to, phenyl, naphthyl, and pyrenyl.
• heteroaryl refers to a ring system (mono-cyclic or bi-cyclic) having the indicated number of ring atoms including carbon atoms and at least one aromatic ring.
• the ring system includes at least one heteroatom such as O, N, or S (e.g., between 1 and 4 heteroatoms, inclusive, per ring) as part of the ring system.
• heteroaryl moieties include, but are not limited to, pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, and thiazolyl.
• alkoxy refers to an -O-alkyl radical.
• cycloalkyl refers to a nonaromatic hydrocarbon ring system (mono-cyclic or bi-cyclic), containing the indicated number of carbon atoms.
• heterocycloalkyl refers to a nonaromatic ring system (mono-cyclic or bi-cyclic), containing the indicated number of ring atoms including carbon atoms and at least one heteroatom such as O, N, or S (e.g., between 1 and 4 heteroatoms, inclusive, per ring) as part of the ring system.
• Alkyliden is a bivalent alkyl group.
• Aryliden is a bivalent aryl group.
• Erythrocytic cell is a mature red blood cell that normally does not have a nucleus: it is a very small, circular disk with both faces concave, and contains hemoglobin, which carries oxygen to the body tissues.
• the compounds described above include the compounds themselves, as well as their salts, if applicable.
• Such salts can be formed between a positively charged substituent (e.g., amino) on a compound and an anion.
• Suitable anions include, but are not limited to, chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate.
• a negatively charged substituent (e.g., carboxylate) on a compound can form a salt with a cation.
• Suitable cations include, but are not limited to, sodium ion, potassium ion, magnesium ion, calcium ion, and an ammomum cation such as tetramethylammonium ion.
• N-oxides refers to one or more nitrogen atoms, when present in a compound, are in N-oxide form, i.e., ⁇ O.
• stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., treating a disease).
• this invention features a method for treating an inflammatory disorder.
• the method includes administering to a subject in need thereof an effective amount of a compound described above, wherein the compound contains a non-antibiotic therapeutic agent that is an anti-mflammatory agent.
• the method includes co-usage with other anti-inflammatory agents or therapeutic agents.
• the method is able to improve therapy by concentrating a compound preferentially in immune cells including neutrophils, monocytes, eosinophils, macrophage, alveolar macrophage, B and T-lymphocytes, ⁇ K cells, giant cells, Kupfer cells, glial cells, and similar target cells using a variety of means of concentrative compound uptake common to such cells.
• the invention is advantageous in that selective concentration of compounds conforming to the definition of "therapeutic agent" above, can improve therapy and that, for the purposes of illustration only, concentration of agents in immune cells can confer improved characteristics on compounds with suitable modes of action for the treatment of inflammatory diseases.
• the invention features a means of improving the action of a compound in vivo by reducing its exposure to the action of detoxification enzymes.
• the invention provides for means to improve the action of a compound through improved retention in the cells and tissues of the organism such that it is less efficiently eliminated by the normal processes of circulation and filtration.
• avoidance of elimination is, at least in part, a consequence of efficient uptake into cells resulting in reduced concentrations of the drug being available from plasma.
• the invention provides for a means of improving the action of a drug by assisting its uptake from the intestine through the overall effects on membrane permeability of the compound that are associated with the invention.
• Uptake from oral administration is a means of providing sustained exposure to the compound from the parts of the intestine to which it is permeable. Oral availability is not a property of all compounds.
• This invention also features a method of treating a disease (e.g., an infectious disease including viral, fungal, or parasitic diseases, cancer, allergy, metabolic, cardiovascular, pulmonary, dermatological, rheumatological or immune disease).
• the method comprises administering to a subject in need thereof an effective amount of a compound described above, wherein the compound contains a non-antibiotic therapeutic agent (e.g., an anti-infectious agent, an anti-cancer agent, an agent for treating a hematopoietic disorder, an agent for treating a lysosomal storage disorder, an allergy-suppressive agent, a lipid lowering agent, a sterol synthesis modifying agent, agents active on protozoa or an immune-suppressant agent).
• a non-antibiotic therapeutic agent e.g., an anti-infectious agent, an anti-cancer agent, an agent for treating a hematopoietic disorder, an agent for treating a lysosomal storage disorder, an allergy-sup
• the method includes co-usage with other therapeutic agents.
• the method provides for means to improve therapy by concentrating a compound preferentially in any of the myeloid, hepatic, respiratory, epithelial, endothelial, other target and immune cells. Therefore, the invention is advantageous in that selective concentration of compounds conforming to the definition of "therapeutic agent" above, via the methods described, can improve therapy and that, for the purposes of illustration only, concentration of agents in immune cells can confer improved characteristics on compounds with suitable modes of action for the treatment of diseases of infectious, allergic, autoimmune, transplant, traumatic or neoplastic origin or association.
• the present invention also features a pharmaceutical composition including at least one compound of this invention and a pharmaceutically acceptable carrier.
• the pharmaceutical composition includes one or more other therapeutic agents.
• This invention further features a method for making any of the compounds described above. The method includes taking any intermediate compound delineated herein, reacting it with any one or more reagents to form a compound of this invention including any processes specifically delineated herein. In another aspect, this invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent.
• the method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells (e.g., by density gradient centrifugation, antibody mediated capture, lectin based capture, absorption to plastic, setting, simple centrifugation, peptide capture, activation mediated capture, or flow cytometry); and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells (e.g., by mass spectrometry, NMR, PET, fluorescence detection, infrared fluorescence, colorimetry, normal detection methods associated with gas chromatography, Fourrier transform spectrometry method, or radioactive detection); wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.
• erythrocytic cells e.g., by density gradient centrifugation, antibody mediated capture, lectin based capture, absorption to plastic,
• the therapeutic agent can be, for example, an anti-inflammatory agent, an anti- infectious agent, an anti-cancer agent, an allergy-suppressive agent, an immune- suppressant agent, an agent for treating a hematopoietic disorder, a lipid lowering agent, an agent for treating a lysosomal storage disorder, a sterol synthesis modifying agent, agents active on protozoa, or an agent for treating a metabolic disease.
• this invention features a method for delivering a therapeutic agent with a selective concentration.
• the method includes identifying a compound using the just-described method, and delivering the compound to a cell (e.g., a cell of respiratory tissue, a cell of neoplastic tissue, or a cell mediating allergic responses).
• a cell e.g., a cell of respiratory tissue, a cell of neoplastic tissue, or a cell mediating allergic responses.
• compositions having one or more of the compounds of this invention for use in treating various diseases described above, and the use of such a composition for the manufacture of a medicament for the just-described use.
• the invention provides several advantages.
• a compound of this invention achieves one or more of the following improvements relative to a therapeutic agent itself: (i) improved uptake across the intestinal, jejunal, duodenal, colonic, or other mucosa; (ii) reduced first pass effect by mucosal oxygenases; (iii) reduced or altered detoxification by degradative enzymes of the body; (iv) reduced efflux; (v) selective accumulation of the therapeutic agent in one or more immune, fibroblast, hepatic, renal, glial, or other target cells; (vi) potential for hydrolytic or other forms of separation on a timescale compatible with therapy and the other desired disposition events; (vi) enhanced pharmacological effect in the target cells through greater concentration, sustained release, reduced substrate competition effect or other mechanisms; (vii) reduced or modified dose; (viii) modified route of administration; (ix) reduced or altered side effects; (x) alternative uses; and (xi) alternative formulations.
• FIG. 1 depicts comparison of selective uptake of diverse structure types into white blood cells from a complex blood mix. These data show that an amino acid (4), a macrolide (5), a sugar (1), a piperazine (2), and a macrolide (3). These data show that diverse properties can be exploited for concentrative uptake and that macrolides can mediate even distribution of their cargo in the cytoplasm.
• FIG. 2 depicts comparison of sugar and piperazine driven uptake of a fluorophore.
• FIG. 3 is bright-field overlay and fluorescent image of polymorphonuclear cells that have taken up a fluorescent macrolide (compound 3). The images suggest even distribution with some concentration near the nucleus.
• FIG. 4 is an example of results from a proliferation assay showing increased efficacy of a T-L-C conjugate following concentrative uptake into lymphocytes.
• FIG. 5 depicts a model to demonstrate the advantage of uptake into target cells.
• FIG. 6 is an example of a response of HeLa cells to a mycophenolic acid conjugate.
• FIG. 7 is an example of guanosine amelioration following treatment of fresh PBMNCs with either mycophenolic acid or a T-L-C conjugate thereof.
• FIG. 8 shows changes in normalized paw thickness (left) and the corresponding arthritic scores (right) of mice treated with different conjugates. Saline and unconjugated compounds are included as controls.
• FIG. 9 shows survival of skin transplant following treatment with an example T-L-C conjugate.
• FIG. 10 shows dose tapering used in skin transplant model to study a T-L-C conjugate.
• the invention describes a method for identifying compounds that act to improve the uptake of therapeutic agents into cells such as those that constitute the immune system in mammals.
• the invention further comprises compounds identified using the method and compounds that could be made based on the teaching provided.
• the invention provides for the rational improvement of therapeutic agents intended for action in inflammatory disease, infection, cancer, allergy, transplantation, cardiovascular, pulmonary, dermatological, rheumatological and metabolic disease.
• the invention also provides for methods to engender unoptimized molecules or those with activity only in vitro with improved properties in vivo through simple conjugation with molecules that meet the criteria outlined herein.
• the method provides for the selection, in vitro, of combinations of a transportophore and a therapeutic agent that exhibits adequate concentrative uptake and also scission with a half life adequate for agent accumulation and agent action.
• a sample of native mammalian blood cells e.g., human blood cell
• which contain at least erythrocytes, neutrophils, monocytes, and lymphocytes e.g., human blood cell
• a transportophore with significantly enhanced concentration in the immune cells and use the transportophore to covalently link to one or more therapeutic agents, via a bond or a linker, to obtain a compound of this invention.
• a compound, containing the transportophore and the therapeutic agent is also concentrated in immune cells after it is incubated with blood cells.
• a linker that provides appropriate cleavage rates between the transportophore and the therapeutic agent in the target cells. More specifically, a method described in Example 1 achieves an estimate of immune cell selective uptake in a complex and competitive biological fluid such that the observed uptake is relevant to the in vivo situation while simultaneously measuring cell specific uptake. Data from other Examples suggest that the molecules that exhibit preferential uptake in this system are also highly available via the oral route while also being stable in the liver.
• the basic method includes contacting the immune cell-erythrocyte preparation with a compound or known compounds and specifically detecting those molecules and their metabolites.
• a further variation is the use of the method in screening complex mixtures of compounds with separation and detection of the resultant cytoplasmic extracts using Mass selective detection combined with a chromatographic separation technique.
• the compounds designated as transportophores are used in the synthesis of libraries such that the final reaction combines library elements with a transportophore using a labile bond allowing the preferential uptake of a compound and its likely scission in an intracellular compartment.
• libraries have the advantage that in cell based assays, there is a reasonable likelihood of adequate therapeutic agent being present at the site of action.
• the compound described in the "Summary" section can be prepared by methods known in the art, as well as by the synthetic routes disclosed herein. For example, one can react a transportophore having a reactive moiety with a therapeutic agent having another reactive moiety.
• One of the two reactive moieties is a leaving group (e.g., -Cl, OR) and the other is a derivatizable group (e.g., -OH, or-NH-). Then, the transportophore is covalently bonded to the therapeutic agent via a reaction between the two reactive moieties.
• each of the two reactive moieties is a leaving group or a derivatizable group, and each reacts with its reactive counterpart in the linker to form a covalent bond.
• the chemicals used in the afore-mentioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like.
• the methods described above may also additionally comprise steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compound of the formulae described herein.
• a therapeutic agent includes any with modes of action that include anti- inflammatory, anti-viral, anti-fungal, immune suppressant, cytostatic, anti-parasitic, lipid lowering, a sterol synthesis modifying, or metabolaregulatory action.
• Anti-inflammatory therapeutic a ents
• Non-steroidal anti-inflammatory therapeutic agents include anti-inflammatory, anti-viral, anti-fungal, immune suppressant, cytostatic, anti-parasitic, lipid lowering, a sterol synthesis modifying, or metabolaregulatory action.
• Diclofenac Diflunisal, Etodolac, Fenoprofen, Floctafenine, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Meclofenamate, Mefenamic, Meloxicam, ⁇ abumetone, Naproxen, Oxaprozin, Phenylbutazone, Piroxicam, Sulindac, Tenoxicam, Tiaprofenic, Tolmetin, Acetaminophen, Aspirin, Salicylamide, acetylsalicylic acid, salicylsalicylic acid.
• Methylprednisolone, Prednisolone, Prednisone, Triamcinolone, Fluticasone Anti- viral systemic is a registered trademark of Methylprednisolone, Prednisolone, Prednisone, Triamcinolone, Fluticasone Anti- viral systemic:
• nucleoside/nucleotide reverse transcriptase inhibitors including but not limited to zidovudine (AZT), didanosine (ddl), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir (ABC), emtricitabine [(-)FTC], tenofovir (PMPA) disoproxil fumarate and phosphoramidate and cyclosahgenyl pronucleotides of d4T or similar chemistries.
• NRTIs nucleoside/nucleotide reverse transcriptase inhibitors
• NRTIs non-nucleoside reverse transcriptase inhibitors
• NRTIs non-nucleoside reverse transcriptase inhibitors
• nevirapine delavirdine
• efavirenz efavirenz
• MKC-442 emivirine
• PTT phenylethylthiazolylthiourea
• MKC-442 emivirine
• protease inhibitors including but not limited to, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, and lopinavir or those based on alternative non- peptidic scaffolds such as cyclic urea (DMP 450), 4-hydroxy-2 -pyrone (tipranavir)
• iv viral entry, through blockade of the viral coreceptors including but not limited to, CXCR4 and CCR5 [bicyclams (i.e. AMD3100), polyphemusins (T22), TAK-779, MIP-1 alpha LD78 beta isoform];
• virus-cell fusion through binding to the viral glycoprotein including but not limited to, gp41 [T-20 (pentafuside) (DP- 178), T-1249 (DP- 107), siamycins, betulinic acid derivatives], and potentially zintevir, L-chicoric acid, CGP64222;
• NCp7 zinc finger-targeted agents including but not limited to, [2,2'-dithiobisbenzamides (DIB As), azadicarbonamide (ADA) and NCp7 peptide mimics];
• proviral DNA integration through integrase inhibitors such as L-chicoric acid and diketo acids (i.e. L-731,988);
• viral mRNA transcription through inhibitors of the transcription (transactivation) process (fluoroquinolone K-12, Streptomyces product EM2487, temacrazine, CGP64222).
• Clotrimazole ketoconazole, miconazole, Butoconazole, econazole, oxiconazole, Sulconazole, Triazoles: fluconazole, itraconazole, Terconazole, Tioconazole ( Fluorinated pyrimidines, flucytosine/5-fluorocytosine, 5-fluorouracil.
• Penicillium-derivatives griseofulvin (oral)
• Antitumor antibiotics Dactinomycin, Daunorubicin,, Doxorubicin,, Idarubicin,, Mitomycin, Mitoxantrone, Antimetabolites, Fluorouracil, Floxuridine, Capecitabine, Cytidine Analogs, Cytarabine, Gemcitabine,
• Plant Alkaloids (DNA repair enzyme inhibitors) Semisynthetic Podophylline Derivitives, Etoposide, Teniposide Taxoid Plant Alkaloids, Docetaxel, Paclitaxel, Synthetic camptothecin
• Plant Alkaloid Derivitives Irinotecan, Topotecan, Vinca Alkaloids, Vinblastine, Vincristine, Vinorelbine,
• Lipid lowering and sterol modifying agents Lipid lowering and sterol modifying agents
• Atorvastatin Pravastatin, Simvastatin, Lovastatin, Cerivastatin, Roxuvastatin, Fluvastatin, Gemfibrozil
• composition that contains an effective amount of at least one of the compound of this present invention and a pharmaceutically acceptable carrier.
• Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
• suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, mesylate, 2- naphthalenesulfonate, nicotinate, nitrate, palmoate, pe
• Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl) salts.
• alkali metal e.g., sodium
• alkaline earth metal e.g., magnesium
• ammonium e.g., ammonium
• N-(alkyl) salts e.g., ammonium, ammonium salts.
• This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
• this invention covers a method of administering an effective amount of one or more compounds of this invention to a subject (a human, a mammal, or an animal, e.g., dog, cat, horse, cow, or chicken) in need of treatment for a disease or disease symptom (e.g., an inflammatory disease, an infectious disease, cancer, allergy, or an immune disease, or symptoms thereof).
• a disease or disease symptom e.g., an inflammatory disease, an infectious disease, cancer, allergy, or an immune disease, or symptoms thereof.
• treating refers to administering a compound of this invention to a subject with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect a disease, the symptoms of the disease or the predisposition toward the disease.
• An effective amount refers to an amount of a compound which confers a therapeutic effect on the treated subject.
• the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
• An effective amount of the compound described above may range from about 0.1 mg/Kg to about 20 mg/Kg.
• Effective doses will also vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and the possibility of co-usage with other agents for treating a disease, including an inflammatory disease, a cardiovascular disease, an infectious disease, cancer, allergy, and an immune disease.
• the methods delineated herein can also include the step of identifying that the subject is in need of treatment of for a disorders and or condition in athe subject. The identification can be in the judgment of a subject or a health professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or a diagnostic method).
• Post traumatic regeneration injury including but not limited to Ischemia, reperfusion injury, scarring, CNS trauma, spinal section, edema, repetitive strain injuries including tendonitis, carpal tunnel syndrome, Cardiovascular diseases specifically atherosclerosis, inflamed or unstable plaque associated conditions, restinosis, infarction, thromboses, post-operative coagulative disorders, acute stroke, Autoimmune diseases
• Alopecia Areata Ankylosing Spondylitis, Antiphospholipid Syndrome, Autoimmune Addison's Disease, aplastic anemia, Autoimmune Hemolytic Anemia, Autoimmune Hepatitis, Behcet's Disease, biliary cirrhosis, Bullous Pemphigoid, Canavan Disease, Cardiomyopathy, Celiac Sprue-De ⁇ natitis, Chronic Fatigue Immune Dysfunction Syndrome (CFIDS), Chronic Inflammatory Demyelinating Polyneuropathy, Churg-Strauss Syndrome, Cicatricial Pemphigoid, CREST Syndrome, Cold Agglutinin Disease, Crohn's Disease, dermatomyositis, Diffuse Cerebral Sclerosis of Schilder, Discoid Lupus, Essential Mixed Cryoglobulinemia, Fibromyalgia- Fibromyositis, Fuch's heterochromic iridocyclitis, Graves' Disease, Guillain-
• Granulomatosis Anti-Phospholipid Antibody Syndrome (Lupus Anticoagulant), Churg-Strauss (Allergic Granulomatosis), Dermatomyositis/Polymyositis, Goodpasture's Syndrome, Interstitial Granulomatous Dermatitis with Arthritis, Lupus Erythematosus (SLE, DLE, SCLE), Mixed Connective Tissue Disease, Relapsing Polychondritis, HLA-B27 asssociated conditions including Ankylosing spondylitis, Psoriasis, Ulcerative colitis, Crohn's disease, IBD, Reiter's syndrome, Uveal diseases: Uveitis, Pediatric Uveitis, HLA-B27 Associated Uveitis, Intermediate Uveitis, Posterior Uveitis, Iritis, Dermatological disease Psoriasis, atopic dermatitis, acne
• Osteoarthritis and various forms of autoimmune arthritis ⁇ eurodegenerative disease flammatory degenerative diseases Including variants and major forms of: Alzheimer's, Huntington's Parkinson's and Creutzfeldt Jakob disease Infection Respiratory diseases of diverse origin including:
• Pharyngitis "sore throat"), Tonsilitis, Sinusitis & Otitis Media, Influenza, Laryngo-Tracheo Bronchitis (Croup), Acute Bronchiolitis, Pneumonia,
• Bronchopneumonia Bronchiolitis, Bronchitis, Acute pharyngitis with fever, Pharyngoconjunctival fever, Acute follicular conjunctivitis, Pneumonia (and pneumonitis in children), COPD, asthma, Gastrointestinal diseases Gastroenteritis of diverse origin Viral diseases
• Target viuses include but are not limited to: Paramyxo-, Picorna-, rhino-, coxsackie-, Influenza-, Herpes-, adeno-, parainfluenza-, respiratory syncytial-, echo-, corona-, Epstein-Barr-, Cytomegalo-, Varicella zoster, Hepatitis variants including hepatitis C Virus (HCN), Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis D Virus (HDV), Hepatitis E Virus (HEV), Hepatitis F Virus (HFV), Hepatitis G Virus (HGV), Human immunodeficiency- Parasitic diseases
• Diphyllobothriasis Diphyllobotlirium spp., Echinococcosis, Echinococcisis (Hydatid Disease), Echinococcus multilocularis, Taeniasis, (Tapeworm Infection), Cysticercosis Leishmaniasis (Kala Azar), Leislimania donovani, Enterobius vermicularis, Anal Pinworms, Dientamoebiasis, Dientamoeba fragilis, Anisakiasis, Anisakis simplex, Giardiasis, Giardia lamblia, Giardia muris
• Trypanosomiasis Trypanosoma brucei, Chagas Disease Neoplastic disease leukemia, lymphoma, myeloma hepatomas, other major organ carcinomas and sarcomas glioma, neuroblastoma,
• Astrocytic and glial tumors Invasive or non-invasive (Anaplastic (malignant) astrocytoma, Glioblastoma multiforme variants: giant cell glioblastoma, gliosarcoma, Pilocytic astrocytoma, Subependymal giant cell astrocytoma, Pleomorphic xanthoastrocytoma) Oligodendroglial tumors Ependymal cell tumors, Mixed gliomas, Neuroepithelial tumors of uncertain origin, Tumors of the choroid plexus, Neuronal and mixed neuronal-glial tumors, Pineal Parenchyma Tumors, Tumors with neuroblastic or glioblastic elements (embryonal tumors), Neuroblastoma, ganglioneuroblastoma, Tumors of the Sellar Region, Hematopoietic tumors, Primary malignant lymphomas, Plasmacytoma, Granulocytic sarcom
• Rhinitis bronchitis, asthma and conditions relating to excessively active or stimulated eosinophils.
• Transplant medicine Renal, hepatic, corneal, stem cell, pulmonary, cardiac, vascular, and myeloid transplants Metabolic disease,
• liver ci ⁇ hosis Various disorders clustered in the liver ci ⁇ hosis, dyslipidemia, diabetes, obesity and hypercholesterolemia groupings.
• the conjugates described here represent improvements on their parent therapeutic agents in two main respects.
• these conjugates provide a facile means of improving the activity of a therapeutic agent through their ability to make the therapeutic agent more easily available either from the gut, or from the blood stream. This is especially important for those therapeutic agents that have good activity in vitro but are unable to exert that activity in vivo.
• simple conjugations according to the schemes described here are an efficient means to generate improved activity.
• the invention also has specific benefits. By targeting cells, and achieving higher concentration in those cells than in plasma or general tissue, the therapeutic agent may exert a more specific action resulting in fewer systemic side effects.
• conjugate also has other potential benefits including the prevention of metabolism through steric effects, increased residence time and traffic to sites of inflammation when it is taken up into target cells which are tropic for the inflamed tissues. Some action of the conjugate itself cannot be ruled out when it is present at high concentrations in a cell.
• an anti-viral therapeutic agent conjugate is cited that also achieves higher levels in immune cells which may act as a reservoir of integrated viral material. If therapeutic agent is selectively conjugated such that it is concentrated in these cells, it has two potential benefits including, the ability to suppress viral replication at lower systemic doses, and the ability to prevent resistance through the maintenance of persistently higher concentrations of therapeutic agent such that mutations with minor effect cannot accumulate. Similar themes but contrasting mechanisms apply to the field of graft rejection where one focus of therapy is the prevention of T-cell responses to the donor organ. Various mechanisms are known but all would benefit if a greater proportion of chemical effect were focused on the T-cells themselves such that the systemic dose were reduced.
• Example 21 cites conjugates of mycophenolic acid that are highly concentrated in immune cells.
• conjugates are also highly bioavailable in the rat and cleave slowly to release mycophenolic acid. Despite slow cleavage, the compounds have very similar anti-proliferative activity in vitro when compared with unconjugated mycophenolic acid suggesting that concentration can compensate for slow hydrolysis such that the conjugate becomes an intracellular reserve for the slow release of mycophenolate.
• neoplasms are of a type that takes up the conjugates to the same extent seen in immune cells.
• Cancers of myeloid origin are a good example of a target neoplasm.
• concentration of the therapeutic agent has potential to compensate for common resistance mechanisms such as gene amplification and the over expression of efflux systems.
• the tumour is associated with an intense local inflammation.
• the inflammatory infiltrate may serve as a means of further concentration of the conjugate drugs in the environs of the tumour.
• cardiovascular diseases such as atherosclerosis
• atherosclerosis it is commonly known that there is a strong inflammatory component to the events which result in the thickening and fragmentation of the plaque.
• This inflammation may be effectively reduced by the application of a range of agents including conjugates of compounds that are anti- inflammatory in effect.
• the compounds of this invention can be administered to a patient, for example, in order to treat a disease described above.
• the compound can, for example, be administered in a pharmaceutically acceptable carrier such as physiological saline, in combination with other therapeutic agents, and/or together with appropriate excipients.
• the compound described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, by inhalation, by intracranial injection or infusion techniques, with a dosage ranging from about 0.1 to about 20 mg/kg of body weight, preferably dosages between 10 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular therapeutic agent.
• the methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Lower or higher doses than those recited above may be required.
• Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, therapeutic agent combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
• compositions of this invention comprise a compound of this invention or a pharmaceutically acceptable salt thereof; and any phannaceutically acceptable carrier, adjuvant or vehicle. Such compositions may optionally comprise additional therapeutic agents.
• the compositions delineated herein include the compounds of the formulae delineated herein, as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of a disease.
• pharmaceutically acceptable carrier or adjuvant refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
• Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying therapeutic agent delivery systems (SEDDS) such as D-alpha-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene
• Cyclodextrins such as ⁇ -, ⁇ -, and ⁇ - cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3 -hydroxypropyl- ⁇ -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
• Oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions.
• compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
• carriers which are commonly used include lactose and corn starch.
• Lubricating agents such as magnesium stearate, are also typically added.
• useful diluents include lactose and dried corn starch.
• compositions of this invention may also be administered in the form of suppositories for rectal administration.
• These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
• suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
• Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
• the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
• Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
• the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents.
• Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
• the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
• compositions of this invention may be administered by nasal aerosol or inhalation.
• Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, abso ⁇ tion promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
• a suitable in vitro assay can be used to preliminarily evaluate a compound of this invention in treating a disease.
• In vivo screening can also be performed by following procedures well known in the art. See the specific examples below. All references cited herein, whether in print, electronic, computer readable storage media or other form, are expressly incorporated by reference in their entirety, including but not limited to, abstracts, articles, journals, publications, texts, treatises, internet web sites, databases, patents, and patent publications.
• NSAID Conjugate Diclofenac Conjugates; Compound 52, 53, 54, & 55
• NSAID Conjugate Compound 56 15
• NSAJD Conjugate Compound 57 16
• NSAID Conjugate Compound 58
• NSAID Conjugate Compound 59 18 NSAID Conjugate: Compound 60 19 NSAID Conjugate: Compound 61 20 Conjugates of cytotoxic agents: Compound 62 21 Conjugates of cytotoxic agents: Compound 64 22 Neotrofin conjugate: Compound 65 23, Gemfibrozil conjugate: Compound 66 24 Mycophenolic Acid conjugates: Compounds 67, 68, 69, 71, 73, 74, 75, 78, 79, 80, & 81
• Steroid Conjugates Compounds 82, 83, 84, 85, & 86 26.
• Statin Conjugates Compounds 87 & 88
• Antifungal Conjugate Compound 89 28.
• Antiviral Nucleoside Conjugates Compounds 90, 92, 94, 97, & 101
• NSAID Conjugate Compound 106 30.
• Coumarin Conjugates Compounds 108, 109 31.
• Imatinab Conjugate Compound 110
• Freshly drawn heparinised blood or buffy coat preparations are used for the determination of immune cell partition ratios.
• Buffy coat preparations are preferred. These may be obtained from donor blood by simple centrifugation of whole blood (4795 g for 10 minutes). Following centrifugation, plasma is collected from the surface, after which immune cells are expressed from the donor bags along with the erythrocytes lying immediately below the leukocyte layer. This ensures high yields and a sufficient population of erythrocytes for partition. 5 ml of the resulting cell suspension are dispensed into T25 culture flasks. Substrates are added to a final concentration between 1 and 10 ⁇ M and the suspensions incubated at 37°C, in a 5% CO2 atmosphere. For analysis of uptake kinetics, samples are withdrawn at 0, 2, 5, 10, 30, 60, 90, 180, or 240 min after substrate addition. For screening purposes, samples are taken at 0 and 120 minutes.
• Cell fractions were prepared using density gradient centrifugation. Mononuclear cells and polymorphonuclear cells are separated from erythrocytes essentially by layering the cell suspension on a viscous medium typically composed of a solution containing Ficoll or similar (commercial suppliers include: Lymphoprep, Axis Shield, 1031966; Lymphoflot HLA, 824010; or PMN Separation Medium Robbins Scientific 1068-00-0). The layered suspension is then centrifuged at 600 g, 20 min, after which the cell fractions and the plasma (incubation medium) fraction are removed by gentle aspiration, washed twice in PBS buffer, followed by estimation of the cell number and pellet volume. Analysis
• Fluorescent analogs of the compounds under study permit the estimation of appropriate uptake intervals as well as the likely intracellular distribution of the compounds. Fluorescent analogs also allow the estimation of losses in washing or other cell manipulations.
• Cell preparations are lysed in water and the debris sedimented at 16100 g, 10 min. The supernatant is recovered and sub-sampled for protein and DNA content.
• Protein in the supernatant is precipitated by bringing the solution to 100 % v/v ethanol and centrifuging again at 16100 g, 10 min.
• Compound uptake is no ⁇ nalized according to cytoplasmic volume of cells in order to obtain the average concentration in the cells.
• Cell volume is estimated by co ⁇ elation of DNA, protein or haem content of lysed cell aliquots to cell number and packed volume prior to lysis.
• Cell lysates are analysed using a HP 1100 HPLC System (Agilent Technologies, Waldbronn, Germany) with a Kromasil 3.5 ⁇ C18, 50 x 2.0 mm column and guard cartridge system (both, Phenomenex, Aillesburg, Geraiany) run at 30°C.
• a gradient elution was performed using water, 0.05% formic acid (A) and acetonitrile 0.05% formic acid (B) (0 min. 5% B, 2.5 min 5% B, 2.8 min 40% B, 10.5 min 85%o B, 12.0 min 95% B, 16.5 min 95% B) at a flow rate of 300 ⁇ l/min.
• Re- equilibration of column was at 5% B, at a flow rate of 750 ⁇ l/min for 2.4 min.
• the HPLC-eluate from retention time 0.0 min to 2.5 min was directed directly to waste.
• Detection was via a UV cell at 214 nm followed by a 1/6 split to an An API-qTOF 1 (Micromass, Manchester, UK) mass spectrometer, (calibrated daily using a mixture of Nal, Rbl and Csl).
• the mass spectrometer is routinely operated in the positive electrospray ionization mode using the following settings: Capillary voltage 4000 V; cone voltage 30 V; RF Lens offset 0.38 V; source block temperature 80°C; desolvation gas temperature 140°C; desolvation gas 240 1/h; LM/ HM Resolution 0.0; Collision energy 4.0 V; Ion energy 5.0 V.
• Masses are monitored according to the known or expected M/Z ratios. Ion cu ⁇ ents across the expected range of masses (including metabolites) are recorded and the chromatograms for specific masses used to estimate the peak area for a given molecular ion (area proportional to concentration over a given range).
• Immune cell selectivity assays provide data in the form of micrographs of fluorescent analogs and quantitative estimates of compound concentration. Micrographs are useful in determining the intracellular disposition of compounds
• FIG. 1 It is apparent from the illustrations that compound distribution is generally uniform with some examples appearing granular or nuclear.
• the analysis of fluorescent libraries by this method provides an efficient means of selecting T molecules that are capable of mediating the transport of diverse substances into a cell. Examples of molecules assayed in this way are summarized in Table 2 along with their uptake data and selectivity. These data show that similar molecules with similar properties can exhibit quite different uptake into immune cells, hence the difficulty in employing general specifications known in the art (Lipinski et al., 2001) Further, it is clear from the images obtained during the course of uptake (FIG. 1, FIG. 2, or FIG. 3) that for some structures, the process is a slow one relative to pure lipophilic diffusion.
• Azithromycin (9a-aza-9a-methyl-9-deoxo-9a- homoerythromycin A, Compound 43) was dissolved in an icecold 6 N hydrogen chloride solution (100 ml). The reaction mixture was stirred at 0°C for 4 hours. The solution turned from yellow to green. The solution was poured on ice (200 g) and 28 ml sodium hydroxide solution (50%) were added. The solution was extracted with ethylacetate (300 ml). The organic layer was discarded. After addition of 30 ml sodium hydroxide solution (50%) to the water layer a colorless precipitate formed. The suspension was extracted with dichloromethane (300 ml). The organic layer was separated, dried over N 2 SO 4 and concentrated under reduced pressure. After drying in high vacuum 12.8 g (100%) of a colorless foam were obtained which were used without further purification.
• a solution of 15 g (20 mmol) of Compound 43 in 50 ml of acetic anhydride is treated with 2 g of potassium carbonate and heated to reflux for 3 h. After cooling the mixture is poured onto ice and neutralized with potassium carbonate. The mixture is extracted with ethyl acetate, washed with water and brine and concentrated after drying (Na 2 SO 4 ). The residue is redissolved in methanol and heated to 50°C overnight. After removal of the methanol in vacuum the residue id redissolved in chloroform. Triethylamine (10 ml) is added and the solution cooled to 0°C.
• the reaction mixture was diluted with ethanol (20 ml) and acetic acid (2.0 ml) and 0.3 g of Pd/C (10%) were added. The reaction mixture was shaken under an atmosphere of hydrogen overnight. After filtration all volatile compounds were removed under reduced pressure. The crude product was subjected to column chromatography on silica gel with chloroform/methanol/7N ammonia in methanol (15:1:1) as the eluent to yield 340 mg (35%>) of compound 50 as a colorless oil.
• melphalan 600 mg is suspended in 25 ml of water containing 500 mg of sodium carbonate. 10 ml of dioxane is added and 1 ml of acetic anhydride. After stirring at ambient temperature for 1 h citric acid is added and the mixture extracted with ethyl acetate. After washing with water and brine the organic phase is dried (sodium sulfate) and concentrated in vacuum. Removal of all volatiles yields the crude N-acetylmelphalan that is carried on to the next step without further purification.
• Prednisolone (180 mg, 0.5 mmol) is suspended in 3 ml of chloroform and 55 mg (0.55 mmol) of succinic anhydride is added. After 24 h at ambient temperature the mixture is cooled to 0°C and 325 mg of Compound 46 (0.5 mmol) is added followed by chlor-N,N,2-trimethylpropenamine (0.2 ml, 1.5 mmol) in several portions. The resulting solution is subjected to column chromatography on silica gel, elution with isopropanol to yield a white solid.
• Dexamethasone (196 mg, 0.5 mmol) is suspended in 3 ml of chloroform and 55 mg (0.55 mmol) of succinic anhydride is added. After 24 h at ambient temperature 375 mg of Compound 43 (0.5 mmol) is added followed by chloro-N,N,2- trimethylpropenamine (0.2 ml, 1.5 mmol) in several portions. The resulting solution is after 1 h subjected to column chromatography on silica gel, elution with isopropanol to yield 198 mg (32%) of a white solid.
• Prednisolone (180 mg, 0.5 mmol) is suspended in 3 ml of chloroform and 55 mg (0.55 mmol) of succinic anhydride is added. After 24 h at ambient temperature the mixture is cooled to 0°C and 295 mg of Compound 40 (0.5 mmol) is added followed by chlor-N,N,2-frimethylpropenamine (0.2 ml, 1.5 mmol) in several portions. The resulting solution is subjected to column chromatography on silica gel, elution with isopropanol to yield 165 mg (32%>) of a white solid
• the solvent is removed in vacuo.
• the crude mixture is then purified by chromatography with chloroform/methanol/ammonia (94.5:10:0.5).
• the collected fractions yielded a white solid (340 mg, 45%).
• Table 3 Representative class of alcohol compounds, which can be used in conjugation reactions.
• BOP (Benzotriazol-l-yloxy)-tris-(dimethylamino)-phosphonium- hexafluorophosphate
• hnatinab may be selectively altered without compromising the interaction with the kinase and thus its biological activity (Schindler et al., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Science 289, 1938-1942, 2000).
• Lymphocytes are purified out of ant coagulated (CPDA, citrate or heparin) mammalian blood using the LymphoprepTM system (supplier). Purified cells are counted using a hemocytometer following Trypan Blue staining, and a cell concentration of 1 x 10 6 cells/ml established in RPMi 1640 medium with 10% FCS and antibiotics as required (all from Biochrome).
• CPDA ant coagulated
• heparin heparin mammalian blood
• Purified cells are counted using a hemocytometer following Trypan Blue staining, and a cell concentration of 1 x 10 6 cells/ml established in RPMi 1640 medium with 10% FCS and antibiotics as required (all from Biochrome).
• a cell proliferation stimulant for example phytohemagglutanin (Sigma) at, for example an end concentration of 5 ⁇ g/ml
• the cells are incubated with different concentrations of the to be investigated compound in 100 ⁇ l end volume in a 96-well microtiter plate in an incubator (37°C, 5% CO 2 , 95% humidity) for 72h.
• Cell proliferation is quantified following BrdU incorporation for 16 h by ELISA and subsequent colorimetric development (Cell Proliferation ELISA BrdU (colorimetric) kit from Roche Diagnostics).
• the IC5 0 ( ⁇ M) values are then calculated, and used to compare compound efficacy.
• the above assay is additionally modified and an additional "wash" step included.
• the assay is also run for just 2h, then compound is washed away in three serial washing steps using 200 ⁇ l of medium at each step, and the cells subsequently incubated for a further 70h.
• the determined IC 50 ( ⁇ M) values following 2h and 72h incubation are compared and a ratio calculated (2h:72h). The lower the number, the better the uptake and drug release from the T-L-C in the cells (see results in Table 4 for examples), and improvement over mycophenolic acid.
• Table 4 Proliferation assay results of T-L-C conjugates of mycophenolic acid
• EXAMPLE 33 CELL-BASED EVIDPH ASSAY WITH GUANOSINE RESCUE
• HeLa cells (DSMZ, ACC 57) and Jurkat cells (DSMZ, ACC 282) in exponential growth phase are exposed for 3 days to test compounds. The number of surviving cells is then determined by the Alamar Blue assay (Serotec Inc.).
• This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. Specifically, the system incorporates an oxidation-reduction indicator that fluoresces in response to chemical reduction of the growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate sunounding environment. Continued growth maintains a reduced environment while inhibition of growth maintains an oxidized environment. Reduction from growth causes the Redox indicator to change from an oxidized to a reduced form. Fluorescence is monitored at 560 nm (Exc.) and 590 nm Em. General procedure:
• HeLa cells (1 xlO 3 ) or JURKAT cells (1 xlO 3 ) are plated in 100 ⁇ l MEM medium (with Earle's salt; Biochrom KG) containing 10%) FBS, 2 mM L-glutamine, and non-essential animo acids in 96-well plates and incubated at 37°C and 5% CO 2 atmosphere. After 24 hours, the test compounds are added over a concentration range and the cells incubated for a further 48 hours. Alamar Blue reagent (20 ⁇ l) is added to each well, and the cultures incubated for a further 4 to 6 hours. The fluorescence is then measured as described above and the LD 50 is determined based on a sigmoidal dose response regression.
• T-L-C conjugates of mycophenolic acid can be demonstrated directly on freshly isolated mammalian PBMNCs.
• the cells are prepared as described in Example 29, and the level of cytotoxicity determined by the Alamar Blue assay, as described above.
• guanosine can also be used here to ameliorate the effect of mycophenolic acid on the activity of IMPDH.
• the toxicity of mycophenolic acid conjugates may be assessed most conveniently in a cell based system, preferably with a rapidly growing cell line such as HeLa or JURKAT.
• mycophenolic acid has an IC 50 of less than 2 uM, and its effect can be completely removed in the presence of 50 ⁇ M guanosine.
• a cell based system preferably with a rapidly growing cell line such as HeLa or JURKAT.
• mycophenolic acid has an IC 50 of less than 2 uM, and its effect can be completely removed in the presence of 50 ⁇ M guanosine.
• alleviation with guanosine is possible, but this is not always complete, which could for example be due to either to other biological effects of the of T-L-C conjugate of mycophenolic acid, or is due to the very high intracellular concentration of mycophenolic acid, following concentrative uptake into the cell.
• EXAMPLE 35 Efficacy Testing of Immunosuppressive drugs using a Mouse Skin Transplant Model.
• Skin transplant rejection is a strong immune response and serves as a very sensitive test of the immunosuppressive potential of drugs in organ transplantation and graft rejection.
• the mouse trunk skin transplant model was established using published methods (Billingham etal., 1954).
• Donor (Bl 10) trunk skin (approximately 8 x 8 mm) is removed and kept cold in saline before grafting on recipient Balb C mice.
• appropriate vehicle-treated control groups are run concunently.
• Graft rejection is quantified as the number of days to reach R4 rejection (>75%> of graft scabbed).
• results An example of results obtained with T-L-C conjugates of mycophenolic acid in the mouse skin transplant model are shown in FIG. 9.
• the TC 50 or MIC procedure for antibiotic sensitivity testing involves an antibiotic dilution assay, which can be performed in microtitre plates. A series of twofold dilutions of each antibiotic are made in the wells, and then all wells are inoculated with a standard amount of the same test organism. After incubation, growth in the presence of the various antibiotics is observed by measuring turbidity. Antibiotic sensitivity is expressed as the concentration of the antibiotic that inhibits 50%) of the growth (TC 50 )- Alternatively it could be expressed as the highest dilution of antibiotic that completly inhibits growth (MIC).
• Bacteria B. pumilus and E .coli (DH5 )
• Bacterial cultures are initiated from the plates for 2 to 3 weeks. After this time period bacteria are streaked out on new plates from the backups strored at -80°C. Due to the lack of resistance of the bacteria, new cultures are not to be initiated from an old plate or any liquid cultures derived from old plates.
• GM Growth medium (GM)(per liter): 10 g Bacto-tryptone, 5 g Bacto-yeast extract, 6 g HEPES (25 mM), 5.4 g NaCl, pH 7.3
• Brater DC 1999, Effects of nonsteroidal anti-inflammatory therapeutic agents on renal function: focus on cyclooxygenase-2-selective inhibition, Am J Med Dec 13;107(6A):65S-70S; discussion 70S-71S. • Breedveld FC, Dayer JM, 2000, Leflimomide: mode of action in the treatment of rheumatoid arthritis, Ann Rheum Dis Nov;59(ll):841-9.
• penciclovir is a selective inhibitor of hepatitis B replication in cultured human hepatoblastoma cells. Antimicrob. Agents and
• PNU156804 blocks IL-2-dependent proliferation and NF-kB and AP-1 activation. The Journal of Immunology, 7102-7109.
• Stepkowski SM Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kalian BD, Kirken RA, 2002, Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood, 99, 680-689.
• Vere Hodge R.A. Sutton, D., Boyd, M.R., Hamden, M.R., Jarvest, R.L., 1989: Selection of an oral protherapeutic agent (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123[9-(4-hydroxy-3-hydroxymethylbut-l- yl)guanine; penciclovir].

Priority Applications (5)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=27757644

Family Applications (1)

Country Status (5)

Cited By (14)

Families Citing this family (14)

Citations (3)

Family Cites Families (36)

• 2003
  • 2003-02-14 AU AU2003215245A patent/AU2003215245A1/en not_active Abandoned
  • 2003-02-14 US US10/504,786 patent/US20060099660A1/en not_active Abandoned
  • 2003-02-14 EP EP03711061A patent/EP1483579A4/en not_active Withdrawn
  • 2003-02-14 WO PCT/US2003/004596 patent/WO2003070173A2/en not_active Application Discontinuation
  • 2003-02-14 US US10/367,624 patent/US20040005641A1/en not_active Abandoned
• 2004
  • 2004-09-15 HR HR20040849A patent/HRP20040849A2/xx not_active Application Discontinuation
• 2007
  • 2007-08-23 US US11/895,295 patent/US20080145343A1/en not_active Abandoned
• 2008
  • 2008-06-12 US US12/157,937 patent/US8357506B2/en not_active Expired - Fee Related

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events